Featured Clinical Trials
Aardvark is exploring the activity of ARD-101 in several settings in order to inform optimal designs for future studies. Initial clinical data demonstrate multiple strong signals of effect, and new studies are anticipated soon.
| Candidates | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|---|---|---|---|---|---|---|
| ARD-101 Oral | Prader-Willi Syndrome | |||||
| ARD-201 Oral | General Obesity | |||||
| Post-Bariatric Surgery | ||||||
| ARD-380 Oral | Overactive Bladder | |||||
| ARD-501 Oral | General Autism | Partnered with Tulex Pharmaceuticals | ||||
| ARD-701 Topical | Inflammatory Skin Disorder | |||||
| ADT-101 Oral | Abuse Deterrence | |||||
- ARD-101
Prader-Willi Syndrome
Stage
Pivotal
Status
Upcoming
Study ID
-
NCT ID
-
- ARD-101
Prader-Willi Syndrome
Stage
Phase 2
Status
Active, Not Recruiting
Study ID
AARD-203
NCT ID
NCT05153434
- ARD-501
General Autism
Stage
Phase 2
Status
Recruiting
Study ID
AARD-501.2
NCT ID
NCT06126653
Expanded Access Program
We are committed to developing and bringing to patients’ novel investigational therapies that address unmet medical needs and serious medical conditions. To that end, we conducts clinical trials using our investigational products with the goal of ultimately gaining regulatory approval(s) to allow marketing these products.
While we recognizes that some patients may not have access to clinical trials for any number of reasons (e.g., ineligibility, prohibitive distance from clinical trial sites) and could potentially benefit from an EAP, it is our current company policy to not offer Expanded Access for any of our investigational products. This policy will be reviewed periodically, and we may at some point in the future offer EAPs for some of our investigational products.
